NO20031849L - Fremgangsmåte for behandling av neurologiske og neuropsykologiske forstyrrelser - Google Patents

Fremgangsmåte for behandling av neurologiske og neuropsykologiske forstyrrelser

Info

Publication number: NO20031849L
Authority: NO; Norway
Prior art keywords: npy; activity; treatment; reduction; functionally active
Prior art date: 2000-10-27

Application number

NO20031849A

Other languages

English (en)

Norwegian (no)

Other versions

NO20031849D0 (no

Inventor

Stephan Von Hoersten

Torsten Hoffmann

Hans-Ulrich Demuth

Kerstin Kuehn-Wache

Daniel Friedrich

Original Assignee

Probiodrug Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-10-27

Filing date

2003-04-24

Publication date

2003-06-23

2003-04-24 Application filed by Probiodrug Ag filed Critical Probiodrug Ag

2003-04-24 Publication of NO20031849D0 publication Critical patent/NO20031849D0/no

2003-06-23 Publication of NO20031849L publication Critical patent/NO20031849L/no

Links

238000000034 method Methods 0.000 title abstract 2
230000000926 neurological effect Effects 0.000 title abstract 2
230000003557 neuropsychological effect Effects 0.000 title 1
101710151321 Melanostatin Proteins 0.000 abstract 3
102400000064 Neuropeptide Y Human genes 0.000 abstract 3
230000000694 effects Effects 0.000 abstract 3
URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 abstract 3
208000019901 Anxiety disease Diseases 0.000 abstract 1
102100027936 Attractin Human genes 0.000 abstract 1
101710134735 Attractin Proteins 0.000 abstract 1
208000000094 Chronic Pain Diseases 0.000 abstract 1
102000004190 Enzymes Human genes 0.000 abstract 1
108090000790 Enzymes Proteins 0.000 abstract 1
241000124008 Mammalia Species 0.000 abstract 1
241001465754 Metazoa Species 0.000 abstract 1
208000002193 Pain Diseases 0.000 abstract 1
102000001708 Protein Isoforms Human genes 0.000 abstract 1
108010029485 Protein Isoforms Proteins 0.000 abstract 1
208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 abstract 1
208000005392 Spasm Diseases 0.000 abstract 1
230000000202 analgesic effect Effects 0.000 abstract 1
230000001430 anti-depressive effect Effects 0.000 abstract 1
230000036506 anxiety Effects 0.000 abstract 1
239000002249 anxiolytic agent Substances 0.000 abstract 1
230000000949 anxiolytic effect Effects 0.000 abstract 1
210000004556 brain Anatomy 0.000 abstract 1
230000015556 catabolic process Effects 0.000 abstract 1
230000001364 causal effect Effects 0.000 abstract 1
238000006731 degradation reaction Methods 0.000 abstract 1
230000003001 depressive effect Effects 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
206010015037 epilepsy Diseases 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
206010022437 insomnia Diseases 0.000 abstract 1
230000001537 neural effect Effects 0.000 abstract 1
108010043412 neuropeptide Y-Y1 receptor Proteins 0.000 abstract 1
BPGXUIVWLQTVLZ-OFGSCBOVSA-N neuropeptide y(npy) Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 BPGXUIVWLQTVLZ-OFGSCBOVSA-N 0.000 abstract 1
230000002035 prolonged effect Effects 0.000 abstract 1
201000000980 schizophrenia Diseases 0.000 abstract 1
239000000758 substrate Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Epidemiology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Addiction (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Cardiology (AREA)
Physical Education & Sports Medicine (AREA)
Anesthesiology (AREA)
Hospice & Palliative Care (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Nutrition Science (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Steroid Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines Containing Plant Substances (AREA)

NO20031849A 2000-10-27 2003-04-24 Fremgangsmåte for behandling av neurologiske og neuropsykologiske forstyrrelser NO20031849L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US24403600P	2000-10-27	2000-10-27
PCT/EP2001/012478 WO2002034242A2 (en)	2000-10-27	2001-10-29	Method for the treatment of neurological and neuropsychological disorders

Publications (2)

Publication Number	Publication Date
NO20031849D0 NO20031849D0 (no)	2003-04-24
NO20031849L true NO20031849L (no)	2003-06-23

Family

ID=22921137

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NO20031849A NO20031849L (no)	2000-10-27	2003-04-24	Fremgangsmåte for behandling av neurologiske og neuropsykologiske forstyrrelser
NO20031867A NO20031867L (no)	2000-10-27	2003-04-25	Fremgangsmate for behandling av nevrologiske og nevropsykologiske forstyrrelser

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
NO20031867A NO20031867L (no)	2000-10-27	2003-04-25	Fremgangsmate for behandling av nevrologiske og nevropsykologiske forstyrrelser

Country Status (19)

Country	Link
US (1)	US20040043919A1 (pt)
EP (2)	EP1328271B1 (pt)
JP (2)	JP2004512299A (pt)
KR (2)	KR20030096227A (pt)
CN (3)	CN1278683C (pt)
AT (1)	ATE399008T1 (pt)
AU (3)	AU2002221773B2 (pt)
BR (2)	BR0114924A (pt)
CA (3)	CA2422889C (pt)
CY (1)	CY1108336T1 (pt)
DE (1)	DE60134563D1 (pt)
DK (1)	DK1328271T3 (pt)
ES (1)	ES2309108T3 (pt)
IL (4)	IL155116A0 (pt)
NO (2)	NO20031849L (pt)
PT (1)	PT1328271E (pt)
RU (3)	RU2286149C2 (pt)
WO (2)	WO2002034243A2 (pt)
ZA (2)	ZA200302590B (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2304206A1 (en) *	1997-09-29	1999-04-08	Point Therapeutics, Inc.	Stimulation of hematopoietic cells in vitro
US6979697B1 (en) *	1998-08-21	2005-12-27	Point Therapeutics, Inc.	Regulation of substrate activity
US6890904B1 (en)	1999-05-25	2005-05-10	Point Therapeutics, Inc.	Anti-tumor agents
US7132104B1 (en)	2000-10-27	2006-11-07	Probiodrug Ag	Modulation of central nervous system (CNS) dipeptidyl peptidase IV (DPIV) -like activity for the treatment of neurological and neuropsychological disorders
KR20030096227A (ko) *	2000-10-27	2003-12-24	프로비오드룩 아게	신경 및 신경정신 질환의 치료방법
ES2296979T3 (es)	2001-06-27	2008-05-01	Smithkline Beecham Corporation	Fluoropirrolidinas como inhibidores de dipeptidil peptidasa.
BR0308816A (pt)	2002-04-08	2005-03-22	Torrent Pharmaceuticals Ltd	Tiazolidina-4-carbonitrilas e análogos e seus usos como inibidores da dipeptil-peptidas
US20050084490A1 (en) *	2002-07-09	2005-04-21	Point Therapeutics, Inc.	Boroproline compound combination therapy
US7550590B2 (en)	2003-03-25	2009-06-23	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
KR20110059664A (ko)	2003-05-05	2011-06-02	프로비오드룩 아게	글루타미닐 및 글루타메이트 사이클라제의 이펙터의 용도
JP5690463B2 (ja)	2003-05-05	2015-03-25	プロビオドルグエージー	グルタミニル、及びグルタミン酸シクラーゼのエフェクターの使用
WO2004103993A1 (en)	2003-05-14	2004-12-02	Syrrx, Inc.	Dipeptidyl peptidase inhibitors
US7169926B1 (en)	2003-08-13	2007-01-30	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
US7678909B1 (en)	2003-08-13	2010-03-16	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
KR20060041309A (ko)	2003-08-13	2006-05-11	다케다 야쿠힌 고교 가부시키가이샤	４-피리미돈 유도체 및 펩티딜 펩티다제 저해제로서의 그의용도
US7790734B2 (en)	2003-09-08	2010-09-07	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
BRPI0415409A (pt)	2003-10-15	2006-12-05	Probiodrug Ag	uso de efetuadores de ciclases de glutaminila e glutamato
US7732446B1 (en)	2004-03-11	2010-06-08	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
CN102127057A (zh)	2004-03-15	2011-07-20	武田药品工业株式会社	二肽基肽酶抑制剂
JP2008501714A (ja)	2004-06-04	2008-01-24	武田薬品工業株式会社	ジペプチジルペプチダーゼインヒビター
WO2006019965A2 (en)	2004-07-16	2006-02-23	Takeda San Diego, Inc.	Dipeptidyl peptidase inhibitors
US20060063719A1 (en) *	2004-09-21	2006-03-23	Point Therapeutics, Inc.	Methods for treating diabetes
WO2006068978A2 (en)	2004-12-21	2006-06-29	Takeda Pharmaceutial Company Limited	Dipeptidyl peptidase inhibitors
GEP20135838B (en)	2005-09-14	2013-06-10	Takeda Pharmaceutical	Dipeptidyl peptidase inhibitors usage at diabetes treatment
CN101360723A (zh)	2005-09-16	2009-02-04	武田药品工业株式会社	制备嘧啶二酮衍生物的方法
WO2007112347A1 (en)	2006-03-28	2007-10-04	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
AU2007235876A1 (en)	2006-04-12	2007-10-18	Probiodrug Ag	Enzyme inhibitors
US8324383B2 (en)	2006-09-13	2012-12-04	Takeda Pharmaceutical Company Limited	Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
TW200838536A (en)	2006-11-29	2008-10-01	Takeda Pharmaceutical	Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en)	2007-03-13	2012-01-10	Takeda Pharmaceuticals Company Limited	Weekly administration of dipeptidyl peptidase inhibitors
RU2350331C1 (ru) *	2007-07-10	2009-03-27	Государственное образовательное учреждение высшего профессионального образования "Мордовский государственный университет им. Н.П. Огарева"	Способ лечения невроза навязчивых состояний
RU2350330C1 (ru) *	2007-11-13	2009-03-27	Государственное образовательное учреждение высшего профессионального образования "Мордовский государственный университет им. Н.П. Огарева"	Способ лечения истерического невроза
JO2870B1 (en)	2008-11-13	2015-03-15	ميرك شارب اند دوهم كورب	Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes
CA2771352A1 (en)	2009-09-02	2011-03-10	Merck Sharp & Dohme Corp.	Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
CN103664873B (zh)	2009-12-30	2016-06-15	深圳信立泰药业股份有限公司	作为二肽基肽酶iv(dpp-iv)抑制剂的3-(3-氨基哌啶-1-基)-5-氧代-1,2,4-三嗪衍生物
US8853212B2 (en)	2010-02-22	2014-10-07	Merck Sharp & Dohme Corp	Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-IV inhibitors for the treatment of diabetes
WO2011146358A1 (en)	2010-05-21	2011-11-24	Merck Sharp & Dohme Corp.	Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
WO2013122920A1 (en)	2012-02-17	2013-08-22	Merck Sharp & Dohme Corp.	Dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
US9668969B1 (en)	2012-02-22	2017-06-06	Arturo Solis Herrera	Methods of using QIAPINE
EP2874622A4 (en)	2012-07-23	2015-12-30	Merck Sharp & Dohme	TREATMENT OF DIABETES WITH DIPEPTIDYLPEPTIDASE IV INHIBITORS
CN107213465A (zh) *	2017-06-23	2017-09-29	武汉大学	二肽基肽酶iv抑制剂在制备防治癫痫的药物中的应用
CN119380997B (zh) *	2024-12-27	2025-03-21	内蒙古医科大学附属医院(内蒙古自治区心血管研究所)	一种神经内科康复程度评价方法及系统

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US25023A (en) *		1859-08-09		Improved device for making electro-magnetic currents, constant or intermittent
US2961377A (en) *	1957-08-05	1960-11-22	Us Vitamin Pharm Corp	Oral anti-diabetic compositions and methods
US3174901A (en) *	1963-01-31	1965-03-23	Jan Marcel Didier Aron Samuel	Process for the oral treatment of diabetes
US3879541A (en) *	1970-03-03	1975-04-22	Bayer Ag	Antihyperglycemic methods and compositions
US3960949A (en) *	1971-04-02	1976-06-01	Schering Aktiengesellschaft	1,2-Biguanides
CH602612A5 (pt) *	1974-10-11	1978-07-31	Hoffmann La Roche
US4935493A (en) *	1987-10-06	1990-06-19	E. I. Du Pont De Nemours And Company	Protease inhibitors
US5433955A (en) *	1989-01-23	1995-07-18	Akzo N.V.	Site specific in vivo activation of therapeutic drugs
DE4039415A1 (de) *	1990-02-03	1991-08-08	Boehringer Mannheim Gmbh	Verfahren zur herstellung rekombinanter proteine ohne n-terminalen methioninrest
US5462928A (en) *	1990-04-14	1995-10-31	New England Medical Center Hospitals, Inc.	Inhibitors of dipeptidyl-aminopeptidase type IV
IL106998A0 (en) *	1992-09-17	1993-12-28	Univ Florida	Brain-enhanced delivery of neuroactive peptides by sequential metabolism
IL111785A0 (en) *	1993-12-03	1995-01-24	Ferring Bv	Dp-iv inhibitors and pharmaceutical compositions containing them
US5705483A (en) *	1993-12-09	1998-01-06	Eli Lilly And Company	Glucagon-like insulinotropic peptides, compositions and methods
US5543396A (en) *	1994-04-28	1996-08-06	Georgia Tech Research Corp.	Proline phosphonate derivatives
US5512549A (en) *	1994-10-18	1996-04-30	Eli Lilly And Company	Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5614379A (en) *	1995-04-26	1997-03-25	Eli Lilly And Company	Process for preparing anti-obesity protein
DE19616486C5 (de) *	1996-04-25	2016-06-30	Royalty Pharma Collection Trust	Verfahren zur Senkung des Blutglukosespiegels in Säugern
US6006753A (en) *	1996-08-30	1999-12-28	Eli Lilly And Company	Use of GLP-1 or analogs to abolish catabolic changes after surgery
US5827898A (en) *	1996-10-07	1998-10-27	Shaman Pharmaceuticals, Inc.	Use of bisphenolic compounds to treat type II diabetes
US6011155A (en) *	1996-11-07	2000-01-04	Novartis Ag	N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
AU766219B2 (en) *	1998-02-02	2003-10-09	1149336 Ontario Inc.	Method of regulating glucose metabolism, and reagents related thereto
AU3034299A (en) *	1998-03-09	1999-09-27	Fondatech Benelux N.V.	Serine peptidase modulators
DE19823831A1 (de) *	1998-05-28	1999-12-02	Probiodrug Ges Fuer Arzneim	Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
DE19834591A1 (de) *	1998-07-31	2000-02-03	Probiodrug Ges Fuer Arzneim	Verfahren zur Steigerung des Blutglukosespiegels in Säugern
AU3960400A (en) *	1999-03-05	2000-09-28	Molteni L. E C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A.	Use of metformin in the preparation of pharmaceutical compositions capable of inhibiting the enzyme dipeptidyl peptidase iv
US6172081B1 (en) *	1999-06-24	2001-01-09	Novartis Ag	Tetrahydroisoquinoline 3-carboxamide derivatives
US6110949A (en) *	1999-06-24	2000-08-29	Novartis Ag	N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US6107317A (en) *	1999-06-24	2000-08-22	Novartis Ag	N-(substituted glycyl)-thiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
HU229042B1 (en) *	2000-03-31	2013-07-29	Prosidion Ltd	Method for the improvement of islet signaling in diabetes mellitus and for its prevention
KR20030096227A (ko) *	2000-10-27	2003-12-24	프로비오드룩 아게	신경 및 신경정신 질환의 치료방법

2001
- 2001-10-29 KR KR10-2003-7005769A patent/KR20030096227A/ko not_active Ceased
- 2001-10-29 IL IL15511601A patent/IL155116A0/xx unknown
- 2001-10-29 WO PCT/EP2001/012479 patent/WO2002034243A2/en not_active Ceased
- 2001-10-29 EP EP01988583A patent/EP1328271B1/en not_active Expired - Lifetime
- 2001-10-29 US US10/415,263 patent/US20040043919A1/en not_active Abandoned
- 2001-10-29 RU RU2003115622/14A patent/RU2286149C2/ru not_active IP Right Cessation
- 2001-10-29 IL IL15515701A patent/IL155157A0/xx unknown
- 2001-10-29 PT PT01988583T patent/PT1328271E/pt unknown
- 2001-10-29 AU AU2002221773A patent/AU2002221773B2/en not_active Ceased
- 2001-10-29 AU AU2002227898A patent/AU2002227898A1/en not_active Abandoned
- 2001-10-29 CA CA2422889A patent/CA2422889C/en not_active Expired - Fee Related
- 2001-10-29 CN CNB018180671A patent/CN1278683C/zh not_active Expired - Fee Related
- 2001-10-29 AT AT01988583T patent/ATE399008T1/de active
- 2001-10-29 JP JP2002537296A patent/JP2004512299A/ja not_active Withdrawn
- 2001-10-29 ES ES01988583T patent/ES2309108T3/es not_active Expired - Lifetime
- 2001-10-29 AU AU2177302A patent/AU2177302A/xx active Pending
- 2001-10-29 EP EP01988582A patent/EP1328270A2/en not_active Withdrawn
- 2001-10-29 BR BR0114924-5A patent/BR0114924A/pt not_active IP Right Cessation
- 2001-10-29 JP JP2002537297A patent/JP2004512300A/ja active Pending
- 2001-10-29 WO PCT/EP2001/012478 patent/WO2002034242A2/en not_active Ceased
- 2001-10-29 CA CA002424475A patent/CA2424475A1/en not_active Abandoned
- 2001-10-29 DK DK01988583T patent/DK1328271T3/da active
- 2001-10-29 ZA ZA200302590A patent/ZA200302590B/en unknown
- 2001-10-29 RU RU2003115614/14A patent/RU2003115614A/ru not_active Application Discontinuation
- 2001-10-29 ZA ZA200302394A patent/ZA200302394B/en unknown
- 2001-10-29 DE DE60134563T patent/DE60134563D1/de not_active Expired - Lifetime
- 2001-10-29 CN CNA01817857XA patent/CN1471392A/zh active Pending
- 2001-10-29 BR BR0114921-0A patent/BR0114921A/pt not_active Application Discontinuation
- 2001-10-29 KR KR10-2003-7005718A patent/KR20040025875A/ko not_active Withdrawn
- 2001-10-29 CN CNA2006101219115A patent/CN101143217A/zh active Pending
- 2001-10-29 CA CA002689012A patent/CA2689012A1/en not_active Abandoned
2003
- 2003-03-27 IL IL155116A patent/IL155116A/en not_active IP Right Cessation
- 2003-04-24 NO NO20031849A patent/NO20031849L/no unknown
- 2003-04-25 NO NO20031867A patent/NO20031867L/no not_active Application Discontinuation
2006
- 2006-06-20 RU RU2006122179/15A patent/RU2416406C2/ru not_active IP Right Cessation
2008
- 2008-09-11 CY CY20081100982T patent/CY1108336T1/el unknown
2009
- 2009-02-11 IL IL196994A patent/IL196994A0/en unknown

Also Published As

Publication number	Publication date
AU2002227898A1 (en)	2002-05-06
ATE399008T1 (de)	2008-07-15
DE60134563D1 (de)	2008-08-07
WO2002034242A3 (en)	2003-01-30
BR0114924A (pt)	2003-12-23
IL155116A (en)	2009-09-01
KR20030096227A (ko)	2003-12-24
IL155116A0 (en)	2003-10-31
RU2006122179A (ru)	2007-12-27
ZA200302394B (en)	2004-03-29
ES2309108T3 (es)	2008-12-16
CN1278683C (zh)	2006-10-11
RU2003115614A (ru)	2004-10-27
US20040043919A1 (en)	2004-03-04
CA2422889C (en)	2010-01-26
CA2689012A1 (en)	2002-05-02
BR0114921A (pt)	2003-12-23
CN1471393A (zh)	2004-01-28
CN101143217A (zh)	2008-03-19
NO20031867D0 (no)	2003-04-25
CN1471392A (zh)	2004-01-28
RU2416406C2 (ru)	2011-04-20
IL155157A0 (en)	2003-10-31
CY1108336T1 (el)	2014-02-12
AU2002221773B2 (en)	2005-12-22
AU2177302A (en)	2002-05-06
EP1328271A2 (en)	2003-07-23
CA2424475A1 (en)	2002-05-02
PT1328271E (pt)	2008-08-26
CA2422889A1 (en)	2002-05-02
KR20040025875A (ko)	2004-03-26
NO20031849D0 (no)	2003-04-24
JP2004512300A (ja)	2004-04-22
ZA200302590B (en)	2004-04-02
WO2002034242A2 (en)	2002-05-02
DK1328271T3 (da)	2008-10-13
EP1328270A2 (en)	2003-07-23
NO20031867L (no)	2003-06-19
RU2286149C2 (ru)	2006-10-27
EP1328271B1 (en)	2008-06-25
WO2002034243A2 (en)	2002-05-02
HK1062643A1 (en)	2004-11-19
WO2002034243A3 (en)	2003-01-30
IL196994A0 (en)	2011-07-31
JP2004512299A (ja)	2004-04-22

Publication	Publication Date	Title
NO20031849D0 (no)	2003-04-24	Fremgangsmåte for behandling av neurologiske og neuropsykologiske forstyrrelser
DE60027431D1 (de)	2006-05-24	Verwendung von p38 MAPK Inhibitoren in der Behandlung von Augenkrankheiten
DE60324449D1 (de)	2008-12-11	Inhibitoren der phosphodiesterase der zyklischen n, und deren verwendung in therapie
TW200635912A (en)	2006-10-16	Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase
DE60227658D1 (de)	2008-08-28	Verfahren zur behandlung neurodegenerativer, psychiatrischer und anderer störungen mit deacetylaseinhibitoren
DE69616375D1 (de)	2001-11-29	Nicht-allosterische GABA A Agonisten zur Behandlung von Schlafstörungen
NO20044470L (no)	2004-11-04	Terapeutisk anvendelse av selektive PDE 10 inhibitorer
ATE298566T1 (de)	2005-07-15	Proteintyrosine-kinaseinhibitoren zur behandlung der osteoarthritis
AR019011A1 (es)	2001-12-26	Inhibidores de las caspasas, composiciones farmaceuticas que comprenden estos inhibidores, metodos para inhibir la actividad de caspasa, disminuir laproduccion de 161f, disminuir la produccion de ifn-gama y para tratar interleukina 1, enfermedades mediadas por apoptosis e interferon-gama usando dich
ATE443758T1 (de)	2009-10-15	Zusammensetzungen und verfahren zur isolierung, vermehrung und differenzierung nicht-embryonale menschlicher stammzellen und deren verwendungen
DE60128540D1 (de)	2007-07-05	Verwendung von relaxin zur behandlung von durch gefässverengung bedingten erkrankungen
ATE289800T1 (de)	2005-03-15	Verwendung eines neurologischen wirkstoffes zur herstellung eines medikamentes zur behandlung von erkrankungen des zentralen nervensystems
DE60008753D1 (de)	2004-04-08	Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen
ATE356634T1 (de)	2007-04-15	Verfahren zur therapeutischen verabreichung von anti-cd40l-mitteln
DK1478380T3 (da)	2006-11-27	Anvendelse af tyrosinkinase-inhibitorer til behandling af CNS-lidelser
ATE304855T1 (de)	2005-10-15	Verwendung von olanzapin zur behandlung von mentalen erkrankungen verursacht durch zerebrovaskuläre erkrankungen
WO2004035086A3 (en)	2004-07-22	Method for treatment of demyelinating central nervous system disease using gm-csf
MXPA02011921A (es)	2003-04-22	Inhibidores de dipeptidasa acida n-acetilada-alfa-enlazada para el tratamiento de trastornos retinianos y glaucona.
EP1372648A4 (en)	2004-09-01	KIEASE TIE2 RECEPTOR INHIBITORS FOR THE TREATMENT OF ANGIOGENIC DISEASES
ATE409469T1 (de)	2008-10-15	Verwendung von 2,2,3,3, tetramethylcyclopropane carbonsäure derivaten zur behandlung von psychiatrischen störungen
MX9704887A (es)	1998-06-30	Composiciones farmaceuticas para el tratamiento de trastornos depresivos.